Efficacy of butyric acid inclusion in eradication regimens for Helicobacter pylori infection: a meta-analysis of controlled trials

Cover Page

Cite item

Full Text

Abstract

Aim. Systematization of data on the efficacy and safety of butyric acid inclusion in eradication therapy (ET) regimens for Helicobacter pylori infection.

Methods. Research searches were carried out in the electronic databases MEDLINE/PubMed, EMBASE, Cochrane, Google Scholar, the Russian Science Citation Index (RSCI) until November 2020. All controlled studies comparing the efficacy and/or safety of including butyric acid in ET regimens for H. pylori infection were included in the final analysis.

Results. The meta-analysis included 6 controlled studies (1 – Italy, 5 – Russia) involving 736 patients (381 in the ET groups with butyric acid; 355 in the comparison groups). The pooled eradication efficiency in the butyric acid groups was 90.23% (95% confidence interval – CI 86.734–93.069), while in the comparison groups it was 65.69% (95% CI 60.441–70.669). Meta-analysis showed that the addition of butyric acid to ET regimens significantly increased the eradication efficiency (odds ratio – OR 5.355, 95% CI 3.504–8.184; p<0.001). There was no significant heterogeneity between results (p=0.1408; I2=42.1%). The addition of butyric acid to ET regimens significantly reduces the risk of diarrhea (OR 0.225, 95% CI 0.0923–0.549; p=0.001; I2=34.21%) and abdominal distention (OR 0.357, 95% CI 0.155–0.818; p=0.015; I2=80.13%) by the end of the 1st week of treatment.

Conclusion. The present meta-analysis demonstrated that the inclusion of butyric acid in ET regimens for H. pylori infection significantly increases the effectiveness of treatment and reduce the incidence of side effects. Apparently, the increase in the effectiveness of eradication is due to an increase in patient compliance with treatment due to an improvement in the safety profile of therapy.

About the authors

D. N. Andreev

Yevdokimov Moscow State University of Medicine and Dentistry

Author for correspondence.
Email: dna-mit8@mail.ru
ORCID iD: 0000-0002-4007-7112

к.м.н., доц. каф. пропедевтики внутренних болезней и гастроэнтерологии

Russian Federation, Moscow

Yu. A. Kucheryavyy

Yevdokimov Moscow State University of Medicine and Dentistry

Email: dna-mit8@mail.ru
ORCID iD: 0000-0001-7760-2091

к.м.н., доц. каф. пропедевтики внутренних болезней и гастроэнтерологии

Russian Federation, Moscow

I. V. Maev

Yevdokimov Moscow State University of Medicine and Dentistry

Email: dna-mit8@mail.ru
ORCID iD: 0000-0001-6114-564X

акад. РАН, д.м.н, проф., зав. каф. пропедевтики внутренних болезней и гастроэнтерологии, засл. врач РФ, засл. деятель науки РФ

Russian Federation, Moscow

References

  1. Маев И.В., Самсонов А.А., Андреев Д.Н. и др. Клиническое значение инфекции Helicobacter pylori. Клин. мед. 2013;91(8):4-12 [Maev IV, Samsonov AA, Andreev DN, et al. Clinical significance of Helicobacter pylori infection. Klin. Med. 2013;91(8):4-12 (In Russ.)].
  2. Sleisenger and Fordtran’s Gastrointestinal and Liver Disease: Pathophysiology, Diagnosis, Management. Edited by M Feldman, LS Friedman, LJ Brandt. 11th ed. 2020.
  3. Zamani M, Ebrahimtabar F, Zamani V, et al. Systematic review with meta-analysis: the worldwide prevalence of Helicobacter pylori infection. Aliment Pharmacol Ther. 2018;47(7):868-76. doi: 10.1111/apt.14561
  4. Malfertheiner P, Megraud F, O’Morain CA, et al. Management of Helicobacter pylori infection-the Maastricht V/Florence Consensus Report. Gut. 2017;66(1):6-30. doi: 10.1136/gutjnl-2016-312288
  5. Fallone CA, Chiba N, van Zanten SV, et al. The Toronto Consensus for the Treatment of Helicobacter pylori Infection in Adults. Gastroenterology. 2016;151(1):51-69. doi: 10.1053/j.gastro.2016.04.006
  6. Chey WD, Leontiadis GI, Howden CW, Moss SF. ACG Clinical Guideline: Treatment of Helicobacter pylori Infection. Am J Gastroenterol. 2017;112(2):212-39. doi: 10.1038/ajg.2016.563
  7. Lee YC, Chen TH, Chiu HM, et al. The benefit of mass eradication of Helicobacter pylori infection: a community-based study of gastric cancer prevention. Gut. 2013;62(5):676-82. doi: 10.1136/gutjnl-2012-302240
  8. Kong YJ, Yi HG, Dai JC, Wei MX. Histological changes of gastric mucosa after Helicobacter pylori eradication: a systematic review and meta-analysis. World J Gastroenterol. 2014;20(19):5903-11. doi: 10.3748/wjg.v20.i19.5903
  9. Khan MY, Aslam A, Mihali AB, et al. Effectiveness of Helicobacter pylori eradication in preventing metachronous gastric cancer and preneoplastic lesions. A systematic review and meta-analysis. Eur J Gastroenterol Hepatol. 2020;32(6):686-94. doi: 10.1097/MEG.0000000000001740
  10. Malfertheiner P, Venerito M, Schulz C. Helicobacter pylori Infection: New Facts in Clinical Management. Curr Treat Options Gastroenterol. 2018;16(4):605-15. doi: 10.1007/s11938-018-0209-8
  11. Маев И.В., Кучерявый Ю.А., Андреев Д.Н., Баркалова Е.В. Эрадикационная терапия инфекции Helicobacter pylori: обзор мировых тенденций. Терапевтический архив. 2014;86(3):94-9 [Maev IV, Kucheryavyi YuA, Andreev DN, Barkalova EV. Eradication therapy for Helicobacter pylori infection: review of world trends. Terapevticheskii Arkhiv (Ter. Arkh.). 2014;86(3):94-9 (In Russ.)]. Available at: https://ter-arkhiv.ru/0040 3660/article/view/31492
  12. Маев И.В., Андреев Д.Н. Молекулярно-генетические предикторы резистентности к антихеликобактерной терапии. Терапевтический архив. 2017;89(8):5-12 [Maev IV, Andreev DN. Molecular genetic predictors of resistance to anti-Helicobacter pylori therapy. Terapevticheskii Arkhiv (Ter. Arkh.). 2017;89(8):5-12 (In Russ.)]. doi: 10.17116/terarkh20178985-12
  13. Murata M, Sugimoto M, Mizuno H, et al. Clarithromycin Versus Metronidazole in First-Line Helicobacter Pylori Triple Eradication Therapy Based on Resistance to Antimicrobial Agents: Meta-Analysis. J Clin Med. 2020;9(2). pii: E543. doi: 10.3390/jcm9020543
  14. Li B, Lan X, Wang L, et al. Proton-pump inhibitor and amoxicillin-based triple therapy containing clarithromycin versus metronidazole for Helicobacter pylori: A meta-analysis. Microb Pathog. 2020;142:104075. doi: 10.1016/j.micpath.2020.104075
  15. Li BZ, Threapleton DE, Wang JY, et al. Comparative effectiveness and tolerance of treatments for Helicobacter pylori: systematic review and network meta-analysis. Version 2. BMJ. 2015;351:h4052. doi: 10.1136/bmj.h4052
  16. Safavi M, Sabourian R, Foroumadi A. Treatment of Helicobacter pylori infection: Current and future insights. World J Clin Cases. 2016;4(1):5-19. doi: 10.12998/wjcc.v4.i1.5
  17. Gisbert JP, McNicholl AG. Optimization strategies aimed to increase the efficacy of H. pylori eradication therapies. Helicobacter. 2017;22(4). doi: 10.1111/hel.12392
  18. Андреев Д.Н., Дичева Д.Т., Маев И.В. Возможности оптимизации эрадикационной терапии инфекции Helicobacter pylori в современной клинической практике. Терапевтический архив. 2017;89(2):84-90 [Andreev DN, Dicheva DT, Maev IV. Possibilities for optimization of eradication therapy for Helicobacter pylori infection in modern clinical practice. Terapevticheskii Arkhiv (Ter. Arkh.). 2017;89(2):84-90 (In Russ.)]. doi: 10.17116/terarkh201789284-90
  19. Kamiya S, Yonezawa H, Osaki T. Role of Probiotics in Eradication Therapy for Helicobacter pylori Infection. Adv Exp Med Biol. 2019;1149:243-55. doi: 10.1007/5584_2019_369
  20. Ji J, Yang H. Using Probiotics as Supplementation for Helicobacter pylori Antibiotic Therapy. Int J Mol Sci. 2020;21(3). pii: E1136. doi: 10.3390/ijms21031136
  21. Андреев Д.Н., Маев И.В., Самсонов А.А. Значение пробиотиков в рамках оптимизации эффективности и безопасности эрадикационной терапии инфекции Helicobacter pylori. Мед. совет. 2020;5:9-16 [Andreev DN, Maev IV, Samsonov AA. The importance of probiotics in optimizing the efficacy and safety of Helicobacter pylori infection eradication therapy. Meditsinskiy sovet = Medical Council. 2020;5:9-16 (In Russ.)]. doi: 10.21518/2079-701X-2020-5-9-16
  22. Yu M, Zhang R, Ni P, et al. Efficacy of Lactobacillus-supplemented triple therapy for H. pylori eradication: A meta-analysis of randomized controlled trials. PLoS One. 2019;14(10):e0223309. doi: 10.1371/journal.pone.0223309
  23. Fang HR, Zhang GQ, Cheng JY, Li ZY. Efficacy of Lactobacillus-supplemented triple therapy for Helicobacter pylori infection in children: a meta-analysis of randomized controlled trials. Eur J Pediatr. 2019;178(1):7-16. doi: 10.1007/s00431-018-3282-z
  24. Shi X, Zhang J, Mo L, et al. Efficacy and safety of probiotics in eradicating Helicobacter pylori: A network meta-analysis. Medicine (Baltimore). 2019;98(15):e15180. doi: 10.1097/MD.0000000000015180
  25. Myllyluoma E, Ahlroos T, Veijola L, et al. Effects of anti-Helicobacter pylori treatment and probiotic supplementation on intestinal microbiota. Int J Antimicrob Agents. 2007;29(1):66-72. doi: 10.1016/j.ijantimicag.2006.08.034
  26. Ye Q, Shao X, Shen R, et al. Changes in the human gut microbiota composition caused by Helicobacter pylori eradication therapy: A systematic review and meta-analysis. Helicobacter. 2020:e12713. doi: 10.1111/hel.12713
  27. Louis P, Flint HJ. Formation of propionate and butyrate by the human colonic microbiota. Environ Microbiol. 2017;19(1):29-41. doi: 10.1111/1462-2920.13589
  28. Leonel AJ, Alvarez-Leite JI. Butyrate: implications for intestinal function. Curr Opin Clin Nutr Metab Care. 2012;15(5):474-9. doi: 10.1097/MCO.0b013e32835665fa
  29. Cushing K, Alvarado DM, Ciorba MA. Butyrate and Mucosal Inflammation: New Scientific Evidence Supports Clinical Observation. Clin Transl Gastroenterol. 2015;6(8):e108. doi: 10.1038/ctg.2015.34
  30. Yonezawa H, Osaki T, Hanawa T, et al. Destructive effects of butyrate on the cell envelope of Helicobacter pylori. J Med Microbiol. 2012 Apr;61(Pt 4):582-9. doi: 10.1099/jmm.0.039040-0
  31. Lo CY, Cheng HL, Hsu JL, et al. The antimicrobial activities of phenylbutyrates against Helicobacter pylori. Chem Pharm Bull (Tokyo). 2013;61(6):604-10. doi: 10.1248/cpb.c12-00857
  32. Shimbo I, Yamaguchi T, Odaka T, et al. Effect of Clostridium butyricum on fecal flora in Helicobacter pylori eradication therapy. World J Gastroenterol. 2005 Dec 21;11(47):7520-4. doi: 10.3748/wjg.v11.i47.7520
  33. Imase K, Takahashi M, Tanaka A, et al. Efficacy of Clostridium butyricum preparation concomitantly with Helicobacter pylori eradication therapy in relation to changes in the intestinal microbiota. Microbiol Immunol. 2008;52(3):156-61. doi: 10.1111/j.1348-0421.2008.00026.x
  34. Авалуева Е., Сказываева Е., Бакулин И., Ситкин С. Повышение комплаентности при эрадикационной терапии хронического Hp-ассоциированного гастрита. Врач. 2018;29(12):9-13 [Avalueva E, Skazazayeva E, Bakulin I, Sitkin S. Increased compliance with eradication therapy of chronic Hp-associated gastritis. Doctor. 2018;29(12):9-13 (In Russ.)]. doi: 10.29296/25877305-2018-12-02
  35. Ильчишина Т.А. Комплаенс при эрадикации Helicobacter pylori: современные подходы к повышению приверженности и результаты собственного исследования. Лечащий врач. 2019;5:71-5 [Ilchishina T.A. Compliance with the eradication of Helicobacter pylori: modern approaches to increasing commitment and the results of our own research. Attending doctor. 2019;5:71-5 (In Russ.)].
  36. Nista EC, Candelli M, Finizio R, et al. Effect of butyric acid and inulin supplementation on side effects of anti-H. pylori therapy: Preliminary data. Digest Liver Dis. 2006;38(S1):S72. doi: 10.1016/S1590-8658(06)80187-8
  37. Буторова Л.И., Плавник Т.А., Кадникова Н.Г., Рекель С.Р. Значение дисбиотических нарушений толстой кишки в патогенезе Helicobacter pylori-ассоциированных заболеваний гастродуоденальной зоны. Роль пребиотиков в повышении эффективности антихеликобактерной терапии. Лечащий врач. 2013;3:92-6 [Butorova LI, Plavnik TA, Kadnikova NG, Rekel SR. The importance
  38. of dysbiotic disorders of the colon in the pathogenesis of Helicobacter pylori-associated diseases of the gastroduodenal zone. The role of prebiotics in increasing the effectiveness of anti-Helicobacter pylori therapy. Attending doctor. 2013;3:92-6 (In Russ.)].
  39. Свиридова Т., Алексеев Н., Ольховик И., Астахова А. Роль масляной кислоты и инулина в повышении эффективности и переносимости эрадикационной терапии. Врач. 2019;5:40-6 [Sviridova T, Alekseev N, Olkhovik I, Astakhova A. The role of butyric acid and inulin in increasing the effectiveness and tolerance of eradication therapy. Doctor. 2019;5:40-6 (In Russ.)]. doi: 10.29296/25877305-2019-05-07
  40. Буторова Л.И., Ардатская М.Д., Осадчук М.А. и др. Сравнение клинико-метаболической эффективности пре- и пробиотиков при проведении оптимизированных протоколов эрадикационной терапии инфекции Helicobacter pylori. Терапевтический архив. 2020;92(4):64-9 [Butorova LI, Ardatskaya MD, Osadchuk MA, et al. Comparison of clinical-metabolic efficacy of pre- and probiotics in the conducted optimized protocols of eradication therapy of Helicobacter pylori infection. Terapevticheskii Arkhiv (Ter. Arkh.). 2020;92(4):64-9 (In Russ.)]. doi: 10.26442/00403660.2020.04.000647
  41. Ардатская М.Д., Топчий Т.Б., Буторова Л.И. и др. Повышение эффективности эрадикационной терапии H. рylori: фокус на приверженность пациентов и безопасность лечения. Лечащий врач. 2020;23(11) [Ardatskaya MD, Topchiy TB, Butorova LI, et al. Improving the effectiveness of H. pylori eradication therapy: focus on patient compliance and treatment safety. Attending doctor. 2020;23(11): (In Russ.)]. doi: 10.26295/OS.2020.хх.хх.ххх
  42. Thung I, Aramin H, Vavinskaya V, et al. Review article: the global emergence of Helicobacter pylori antibiotic resistance. Aliment Pharmacol Ther. 2016;43(4):514-33. doi: 10.1111/apt.13497
  43. Hudson N, Brydon WG, Eastwood MA, et al. Successful Helicobacter pylori eradication incorporating a one-week antibiotic regimen. Aliment Pharmacol Ther. 1995;9(1):47-50. doi: 10.1111/j.1365-2036.1995.tb00350.x
  44. Maev IV, Andreev DN, Kucheryavyi YuA, Dicheva DT. Host factors influencing the eradication rate of Helicobacter pylori. World Applied Sci J. 2014;30:134-40. doi: 10.5829/idosi.wasj.2014.30.mett.61
  45. Маев И.В., Кучерявый Ю.А., Андреев Д.Н. Причины неэффективности антихеликобактерной терапии. Рос. журн. гастроэнтерол., гепатол., колопроктол. 2013;6:62-72 [Maev IV, Kucheryavyi YA, Andreev DN. Causes of inefficiency of anti-Helicobacter pylori therapy. Rus J Gastroenterol Hepatol. 2013;23:62-72 (In Russ.)].
  46. Li L, Zhou X, Xiao S, et al. The Effect of Helicobacter pylori Eradication on the Gastrointestinal Microbiota in Patients with Duodenal Ulcer. J Gastrointestin Liver Dis. 2016;25(2):139-46. doi: 10.15403/jgld.2014.1121.252.hpe
  47. Yadav H, Lee JH, Lloyd J, et al. Beneficial metabolic effects of a probiotic via butyrate-induced GLP-1 hormone secretion. J Biol Chem. 2013 Aug 30;288(35):25088-97. doi: 10.1074/jbc.M113.452516
  48. Roshanravan N, Mahdavi R, Alizadeh E, et al. Effect of Butyrate and Inulin Supplementation on Glycemic Status, Lipid Profile and Glucagon-Like Peptide 1 Level in Patients with Type 2 Diabetes: A Randomized Double-Blind, Placebo-Controlled Trial. Horm Metab Res. 2017;49(11):886-91. doi: 10.1055/s-0043-119089
  49. Fu X, Liu Z, Zhu C, et al. Nondigestible carbohydrates, butyrate, and butyrate-producing bacteria. Crit Rev Food Sci Nutr. 2019;59(Suppl.):S130-S152. doi: 10.1080/10408398.2018.1542587

Supplementary files

Supplementary Files
Action
1. JATS XML
Download
2. Fig. 1. CONSORT diagram detailing the study selection strategy.

Download (198KB)
Indexing metadata
3. Fig. 2. Forest diagram showing OR and 95% CI of the efficiency of butyric acid inclusion in ET regimens.

Download (153KB)
Indexing metadata
4. Fig. 3. Funnel-shaped scatter plot to assess the likelihood of the presence of publication bias when assessing the effectiveness of the inclusion of butyric acid in ET regimens.

Download (232KB)
Indexing metadata

Copyright (c) 2021 Consilium Medicum

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
 
 


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies